Skip to main content

PAPEL DE LOS FACTORES DE RESPUESTA A HIPOXIA HIFS EN PATOLOGIA PULMONAR ASOCIADA A LAS VIAS RESPIRATORIAS

SAF2016-76815-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hypoxia-inducible factor 2-dependent pathways driving Von Hippel–Lindau-deficient renal cancer

  • Meléndez-Rodríguez, Florinda
  • Roche, Olga
  • Sánchez-Prieto, Ricardo
  • Aragonés, Julián
The most common type of the renal cancers detected in humans is clear cell renal cell carcinomas (ccRCCs). These tumors are usually initiated by biallelic gene inactivation of the Von Hippel–Lindau (VHL) factor in the renal epithelium, which deregulates the hypoxia-inducible factors (HIFs) HIF1α and HIF2α, and provokes their constitutive activation irrespective of the cellular oxygen availability. While HIF1α can act as a ccRCC tumor suppressor, HIF2α has emerged as the key HIF isoform that is essential for ccRCC tumor progression. Indeed, preclinical and clinical data have shown that pharmacological inhibitors of HIF2α can efficiently combat ccRCC growth. In this review, we discuss the molecular basis underlying the oncogenic potential of HIF2α in ccRCC by focusing on those pathways primarily controlled by HIF2α that are thought to influence the progression of these tumors., This work was supported by grants from Ministerio de Educación y Ciencia (SAF2013-46058-R; SAF2016-76815), TV3 Marató (534/C/2016), and CIBERCV. OR has a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla La Mancha (UCLM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

HIF1α suppresses tumor cell proliferation through inhibition of aspartate biosynthesis

  • Meléndez-Rodríguez, Florinda
  • Urrutia, Andrés A.
  • Lorendeau, Doriane
  • Rinaldi, Gianmarco
  • Roche, Olga
  • Böğürcü-Seidel, Nuray
  • Ortega-Muelas, Marta
  • Mesa-Ciller, Claudia
  • Turiel, Guillermo
  • Bouthelier, Antonio
  • Hernansanz-Agustín, Pablo
  • Elorza, Ainara
  • Escasany, Elia
  • Yang Li, Qilong Oscar
  • Torres-Capelli, Mar
  • Tello, Daniel
  • Fuertes, Esther
  • Fraga, Enrique
  • Martínez-Ruiz, Antonio
  • Pérez, Belén
  • Giménez-Bachs, José M.
  • Salinas-Sánchez, Antonio S.
  • Acker, Till
  • Sánchez-Prieto, Ricardo
  • Fendt, Sarah-Maria
  • De Bock, Katrien
  • Aragonés, Julián
Cellular aspartate drives cancer cell proliferation, but signaling pathways that rewire aspartate biosynthesis to control cell growth remain largely unknown. Hypoxia-inducible factor-1α (HIF1α) can suppress tumor cell proliferation. Here, we discovered that HIF1α acts as a direct repressor of aspartate biosynthesis involving the suppression of several key aspartate-producing proteins, including cytosolic glutamic-oxaloacetic transaminase-1 (GOT1) and mitochondrial GOT2. Accordingly, HIF1α suppresses aspartate production from both glutamine oxidation as well as the glutamine reductive pathway. Strikingly, the addition of aspartate to the culture medium is sufficient to relieve HIF1α-dependent repression of tumor cell proliferation. Furthermore, these key aspartate-producing players are specifically repressed in VHL-deficient human renal carcinomas, a paradigmatic tumor type in which HIF1α acts as a tumor suppressor, highlighting the in vivo relevance of these findings. In conclusion, we show that HIF1α inhibits cytosolic and mitochondrial aspartate biosynthesis and that this mechanism is the molecular basis for HIF1α tumor suppressor activity., This work was supported by grants from Ministerio de Economia y Competitividad (SAF2016-76815 and SAF2017-90794-REDT) and Fundació La Marató de TV3 (534/C/2016). F.M.-R. is supported by Ministerio de Economia y Competitividad (BES-2014-068618). A.A.U is supported by the CAM “Atracción de Talento” program. D.L. is supported by the VIB-Marie Curie omics program. S.-M.F. acknowledges funding support from a Marie Curie CIG, FWO Odysseus II, FWO Research Grants, Eugène Yourassowsky Schenking, and KU Leuven Methusalem co-funding. O.R. has a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM). R.S.P acknowledges funding support from Ministerio de Educación y Ciencia (SAF2015-64215-R) and Fundacion Leticia Castillejo Castillo. A.M.-R. acknowledges funding support from Ministerio de Economía y Competitividad (PI15/00107)., Peer reviewed